RSV Prevention Antibody Technology In-Licensing Agreement (Conditional Milestones of $16.25M)
-
Signed technology in-license agreement with Gates Medical Research Institute for RSV prevention antibody
-
Total contract value $16.25M (approx. KRW 23.7B, exchange rate 1,457.3 KRW/USD),
-
no upfront payment, full amount as development/approval milestones
-
Royalties on annual net sales after launch to be paid separately
-
Conditional contract; termination possible upon clinical halt or approval failure (investment risk)
KOSPI Filing Information
-
Filing: Major Management Matters Related to Investment Decision (RSV Preventive Antibody Technology Introduction Contract Signed)
-
Company: SK Bioscience (302440)
-
Submission: SK Bioscience Co.,Ltd
-
Receipt: 02-03-2026
-
Under KRX KOSPI Market Division